Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Azacitidine and Enasidenib in Treating Patients with IDH2-Mutant Myelodysplastic Syndrome
      Description

      This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic LeukemiaIDH2 Gene MutationMyelodysplastic Syndrome with Excess BlastsRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic Syndrome
      Talk to us
      COMPLETED
      Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
      Description

      This phase I/II trial studies the side effects of glutaminase inhibitor CB-839 in combination with azacitidine in treating patients with myelodysplastic syndrome that has spread to other places in the body. Glutaminase inhibitor CB-839 and azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeIPSS Risk Category Intermediate-2Myelodysplastic Syndrome
      Talk to us